

Title (en)
CYCLOPENTAPYRROLE OREXIN RECEPTOR AGONISTS

Title (de)
CYCLOPENTAPYRROLOREXIN-REZEPTORAGONISTEN

Title (fr)
AGONISTES DU RÉCEPTEUR DE L'OREXINE CYCLOPENTAPYRROLE

Publication
EP 4199925 A4 20240828 (EN)

Application
EP 21858880 A 20210816

Priority
• US 202063066913 P 20200818
• US 2021046064 W 20210816

Abstract (en)
[origin: WO2022040058A1] The present invention is directed to cyclopentapyrrole, furopyrrrole and azabicycloheptane compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.

IPC 8 full level
A61K 31/44 (2006.01); **A61K 31/403** (2006.01); **A61K 31/407** (2006.01); **A61K 31/4439** (2006.01); **A61K 31/4965** (2006.01); **A61K 31/506** (2006.01); **A61P 25/00** (2006.01); **C07D 209/52** (2006.01); **C07D 401/14** (2006.01); **C07D 491/02** (2006.01)

CPC (source: EP US)
A61K 31/403 (2013.01 - EP); **A61K 31/407** (2013.01 - EP); **A61K 31/506** (2013.01 - EP); **A61P 25/00** (2018.01 - EP); **C07D 209/52** (2013.01 - EP US); **C07D 401/14** (2013.01 - EP US); **C07D 491/02** (2013.01 - EP); **C07D 491/048** (2013.01 - US)

Citation (search report)
• [E] WO 2022040070 A1 20220224 - MERCK SHARP & DOHME [US], et al
• [A] US 2020255403 A1 20200813 - BOGEN STEPHANE L [US], et al
• [Y] EP 3663281 A1 20200610 - TAKEDA PHARMACEUTICALS CO [JP]
• [AD] US 2020115399 A1 20200416 - FUJIMOTO TATSUHIKO [JP], et al
• [A] US 8288429 B2 20121016 - AISSAOUI HAMED [FR], et al
• [A] YUKITAKE HIROSHI ET AL: "TAK-925, an orexin 2 receptor-selective agonist, shows robust wake-promoting effects in mice", PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, ELSEVIER, US, vol. 187, 22 October 2019 (2019-10-22), XP085903575, ISSN: 0091-3057, [retrieved on 20191022], DOI: 10.1016/J.PBB.2019.172794
• [Y] CHRISTOPH BOSS ET AL: "Structure-Activity Relationship, Biological, and Pharmacological Characterization of the Proline Sulfonamide ACT-462206: a Potent, Brain-Penetrant Dual Orexin 1/Orexin 2 Receptor Antagonist", CHEMMEDCHEM COMMUNICATIONS, WILEY-VCH, DE, vol. 9, no. 11, 21 August 2014 (2014-08-21), pages 2486 - 2496, XP072420334, ISSN: 1860-7179, DOI: 10.1002/CMDC.201402258
• See also references of WO 2022040058A1

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)
WO 2022040058 A1 20220224; EP 4199925 A1 20230628; EP 4199925 A4 20240828; US 2023257348 A1 20230817

DOCDB simple family (application)
US 2021046064 W 20210816; EP 21858880 A 20210816; US 202118040861 A 20210816